Merck MRK reported first-quarter 2025 adjusted earnings per share (EPS) of $2.22, which beat the Zacks Consensus Estimate of ...

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against cancer-causing HPV in China, which previously powered Merck’s growth.